Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $44.00 Average Price Target from Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $44.00.

Several equities analysts have recently issued reports on ASMB shares. Guggenheim reiterated a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, May 4th. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th.

Hedge Funds Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of ASMB. Farallon Capital Management LLC acquired a new stake in shares of Assembly Biosciences during the 3rd quarter worth about $31,426,000. RA Capital Management L.P. purchased a new stake in Assembly Biosciences during the third quarter worth approximately $26,122,000. Commodore Capital LP acquired a new position in Assembly Biosciences in the third quarter valued at approximately $25,600,000. Paradigm Biocapital Advisors LP acquired a new position in Assembly Biosciences in the fourth quarter valued at approximately $22,625,000. Finally, Parkman Healthcare Partners LLC purchased a new position in Assembly Biosciences in the third quarter valued at approximately $6,425,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $27.74 on Friday. The business has a 50-day moving average of $26.68 and a 200 day moving average of $28.42. Assembly Biosciences has a 12 month low of $16.90 and a 12 month high of $39.71. The stock has a market capitalization of $440.79 million, a price-to-earnings ratio of -252.16 and a beta of 1.08.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The company had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. Equities research analysts anticipate that Assembly Biosciences will post 1.9 earnings per share for the current year.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.